<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856518</url>
  </required_header>
  <id_info>
    <org_study_id>B6576-R</org_study_id>
    <nct_id>NCT00856518</nct_id>
  </id_info>
  <brief_title>Expiratory Muscle Training for Persons With Neurodegenerative Disease</brief_title>
  <acronym>EMST</acronym>
  <official_title>Expiratory Muscle Training for Persons With Neurodegenerative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory difficulty is one of the primary factors leading to death in patients with
      Parkinson's Disease (PD) and Multiple Sclerosis. Both diseases are progressive degenerating
      diseases that cause difficulties in breathing, airway protection and swallowing. Patients
      with PD and MS typically become sedentary and lose endurance, maximal fitness levels and
      overall pulmonary function. Much of the research focus has been on the motor symptoms of PD
      and MS yet the pulmonary and swallowing complications are perhaps ultimately the most
      important disability as the diseases progress. The inability to generate adequate respiratory
      pressure is responsible for reduced cough magnitudes and cough response times. Cough is
      critical for the clearance of foreign materials in the airway helping to reduce infiltration
      of bacteria and subsequent respiratory infection. With reduced cough function an increased
      risk for pulmonary disease occurs due to a reduced ability to protect the airways. There are
      a number of promising outcomes from an expiratory strength-training program. By increasing
      expiratory muscle strength and expiratory pressure generation, effective breathing, clearance
      of the airway, and improved swallowing can occur. These explicit outcomes are predicted based
      on our experience with the use of an innovative device-driven, home-based expiratory strength
      training program focused on the expiratory muscles of respiration. This project focuses on
      following patients with PD and MS for an initial 5 weeks of strength training and them
      testing the outcome of a caregiver program for maintaining treatment effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed investigation will:

      Determine if 5 weeks of Expiratory Muscle Strength Training (EMST) increases maximal
      expiratory driving pressure (MEP) and improves swallow, cough and breathing function in
      individuals with PD and MS. Following the post assessment of the 5 week EMST program we will
      then evaluate three different modules for monitoring the continuation of the treatment while
      assessing patient quality of life and caregiver burden/satisfaction. This will help us
      determine if one particular home training method results in different physiological and
      functional outcomes.

      Aim 1. Determine the effects of an EMST program on swallow function, voluntary cough
      production and breathing function in individuals with PD and MS identified as below normal
      limits for their age and sex (via physiological measures).

      Hypothesis 1: There will significant and positive treatment effects following 5 weeks of EMST
      on the measures of swallow, cough production and breathing function in those with PD and MS
      following 5 weeks of treatment.

      Aim 2: Determine the outcome of three uniquely structured home treatment monitoring programs
      in maintaining the EMST post treatment effect for patients with MS and PD. These programs are
      referred to as: Education Module (A), Question Only (B), and Education Module plus Question
      (C). The monitoring system will be provided by VitelNet, a leading provider of home health
      monitoring, clinician-based telemedicine Hypothesis 2: Program C will provide greater
      maintenance of the EMST treatment effect for both patient groups compared to programs A and
      B.

      Aim 3: Determine the effects of the home monitoring programs for improving patient quality of
      life and caregiver burden/satisfaction.

      Hypothesis 3: Program C will provide greater improvements in patient quality of life and
      caregiver burden compared to programs A and B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Expiratory Pressure (MEP)</measure>
    <time_frame>at baseline and again after 5-week EMST exercise</time_frame>
    <description>Expiratory pressure generating capacity assessed via handheld manometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penetration-Aspiration Scale Score</measure>
    <time_frame>at baseline and again after 5-week EMST exercise</time_frame>
    <description>The Penetration-Aspiration Scale (PAS) was used to measure swallow safety. PAS is an 8 point ordinal scale for quantification of penetration and aspiration. PAS measures the depth to which material enters the airway and if the material is expelled following penetration or aspiration. Categorical groupings of PAS scores include &quot;normal to mild&quot; (1-2), &quot;moderate&quot; (3-5) and &quot;severe&quot; (6-8, indicating that material has passed into the lower airway). These PAS scores may be useful in denoting clinically significant changes (e.g. moderate to mild) resulting from treatment or disease progression. The following table reports the percentage of participants (out of the respective total group participants in EMST and Sham) with changed PAS score of 1 point or more (improving or worsening) and without PAS score changes from pre- to post treatment. The data represent an exploratory quantification without statistical analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swallow-related Quality of Life (SWAL-QOL)</measure>
    <time_frame>at baseline and after 5-week of EMST exercise</time_frame>
    <description>The SWAL-QOL is a validated and standardized tool that measures burden; symptom status including pharyngeal, oral, and saliva; fear; and mental health subdomains. Responses are determined according to an ordinal scale where 1 equals a severe problem and 5 equals no problem. The SWAL-QOL provides an overall score as well as subscale scores. Subjects rate quality of life as follows (expressed as percentage of the possible perfect score): little to no impact (81% - 100%), mild impact (61% - 80%), moderate impact (41% - 60%), severe impact (21% - 40%), and profound impact (0% - 20%).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: EMST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMST</intervention_name>
    <description>Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.</description>
    <arm_group_label>Arm 1: EMST</arm_group_label>
    <other_name>EMST 150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>The same device just like the EMST but does not provide a load on the target muscle group</description>
    <arm_group_label>Arm 2: Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple Sclerosis Participants

          -  Diagnosis of primary, secondary, or relapsing-remitting MS by a neurologist

          -  Over 85% of the patient populations that come from the study sites demonstrate
             relapsing-remitting MS with an average relapse frequency of once every 3 years

        Parkinson's Disease Participants

          -  Hoehn &amp; Yahr, stage II and III as indicated by certified movement disorders
             neurologist

        All Participants

          -  Between 35 and 80 years of age

          -  Non-smoking or no smoking within the previous five years

          -  No history of head and neck cancer, asthma or COPD, untreated hypertension

          -  Sufficient facial muscle strength so as to achieve and maintain adequate lip closure
             around a circular mouthpiece

          -  Cognition within normal limits as determined by the: Mini Mental Status Exam (MMSE;
             1975No neurological (other than MS or PD) condition which adversely affects
             respiratory muscle or gas exchange system

          -  Reduced MEP's compared to published normative data for age and sex

          -  Reduced expiratory peak flow rates (6-8 L/s for young to middle age adults and 3.6 L/s
             for 65 and older) during voluntary cough production for age and sex (Bolser, personal
             communication; Smith-Hammond &amp; Goldstein, 2006)

          -  Participant report of symptoms related to swallow impairment

        Exclusion Criteria:

          -  DBS

          -  COPD

          -  Asthma

          -  Smoking or smoking within preceding 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janis J. Daly, PhD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Florida/South Georgia Veterans Health System, Gainesville, FL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <results_first_submitted>February 26, 2016</results_first_submitted>
  <results_first_submitted_qc>October 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Dysphagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: EMST</title>
          <description>Experimental Group
Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Sham Group</title>
          <description>sham group
sham device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: EMST</title>
          <description>Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Sham Group</title>
          <description>Sham Device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="9"/>
                    <measurement group_id="B2" value="58" spread="8"/>
                    <measurement group_id="B3" value="55" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Expiratory Pressure (MEP)</title>
        <description>Expiratory pressure generating capacity assessed via handheld manometer.</description>
        <time_frame>at baseline and again after 5-week EMST exercise</time_frame>
        <population>Out of the 42 recruited patients, 6 withdrew following the baseline MEP testing, citing travel or loss of interest as the reason. Therefore, 36 subjects were reported for the MEP test (n = 20 for EMST, n = 16 for sham).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: EMST</title>
            <description>EMST Group
Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Sham</title>
            <description>Sham group
sham device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Expiratory Pressure (MEP)</title>
          <description>Expiratory pressure generating capacity assessed via handheld manometer.</description>
          <population>Out of the 42 recruited patients, 6 withdrew following the baseline MEP testing, citing travel or loss of interest as the reason. Therefore, 36 subjects were reported for the MEP test (n = 20 for EMST, n = 16 for sham).</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="30.72"/>
                    <measurement group_id="O2" value="75.56" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.00" spread="32.97"/>
                    <measurement group_id="O2" value="99.38" spread="37.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.899</p_value>
            <p_value_desc>EMST arm vs. Sham arm baseline MEP value comparison</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.946</p_value>
            <method>Plum Ordinal Regression Test</method>
            <method_desc>EMST arm vs. Sham arm group comparison of treatment response</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00042</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>EMST arm post vs. pre-MEP comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Sham arm post vs. pre-MEP comparison</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Penetration-Aspiration Scale Score</title>
        <description>The Penetration-Aspiration Scale (PAS) was used to measure swallow safety. PAS is an 8 point ordinal scale for quantification of penetration and aspiration. PAS measures the depth to which material enters the airway and if the material is expelled following penetration or aspiration. Categorical groupings of PAS scores include &quot;normal to mild&quot; (1-2), &quot;moderate&quot; (3-5) and &quot;severe&quot; (6-8, indicating that material has passed into the lower airway). These PAS scores may be useful in denoting clinically significant changes (e.g. moderate to mild) resulting from treatment or disease progression. The following table reports the percentage of participants (out of the respective total group participants in EMST and Sham) with changed PAS score of 1 point or more (improving or worsening) and without PAS score changes from pre- to post treatment. The data represent an exploratory quantification without statistical analysis.</description>
        <time_frame>at baseline and again after 5-week EMST exercise</time_frame>
        <population>Out of the 42 recruited patients, 8 failed to complete the PAS test either at baseline or post training testing. Therefore, 34 subjects were reported for the PAS test (n = 20 for EMST, n = 14 for sham).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: EMST</title>
            <description>EMST Group
Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Sham</title>
            <description>Sham group
sham device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
          </group>
        </group_list>
        <measure>
          <title>Penetration-Aspiration Scale Score</title>
          <description>The Penetration-Aspiration Scale (PAS) was used to measure swallow safety. PAS is an 8 point ordinal scale for quantification of penetration and aspiration. PAS measures the depth to which material enters the airway and if the material is expelled following penetration or aspiration. Categorical groupings of PAS scores include &quot;normal to mild&quot; (1-2), &quot;moderate&quot; (3-5) and &quot;severe&quot; (6-8, indicating that material has passed into the lower airway). These PAS scores may be useful in denoting clinically significant changes (e.g. moderate to mild) resulting from treatment or disease progression. The following table reports the percentage of participants (out of the respective total group participants in EMST and Sham) with changed PAS score of 1 point or more (improving or worsening) and without PAS score changes from pre- to post treatment. The data represent an exploratory quantification without statistical analysis.</description>
          <population>Out of the 42 recruited patients, 8 failed to complete the PAS test either at baseline or post training testing. Therefore, 34 subjects were reported for the PAS test (n = 20 for EMST, n = 14 for sham).</population>
          <units>percentage of group participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with improved PAS after training</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>with unchanged PAS after training</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>with worsened PAS after training</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Swallow-related Quality of Life (SWAL-QOL)</title>
        <description>The SWAL-QOL is a validated and standardized tool that measures burden; symptom status including pharyngeal, oral, and saliva; fear; and mental health subdomains. Responses are determined according to an ordinal scale where 1 equals a severe problem and 5 equals no problem. The SWAL-QOL provides an overall score as well as subscale scores. Subjects rate quality of life as follows (expressed as percentage of the possible perfect score): little to no impact (81% - 100%), mild impact (61% - 80%), moderate impact (41% - 60%), severe impact (21% - 40%), and profound impact (0% - 20%).</description>
        <time_frame>at baseline and after 5-week of EMST exercise</time_frame>
        <population>Out of the total 42 recruited study participants, ten either did not show up for the SWAL-QOL test or only partially answered the questionnaire. Thus, 32 remaining participants (n = 19 for EMST, and n = 13 for Sham) were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: EMST</title>
            <description>The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Sham Group</title>
            <description>The sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
sham device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
          </group>
        </group_list>
        <measure>
          <title>Swallow-related Quality of Life (SWAL-QOL)</title>
          <description>The SWAL-QOL is a validated and standardized tool that measures burden; symptom status including pharyngeal, oral, and saliva; fear; and mental health subdomains. Responses are determined according to an ordinal scale where 1 equals a severe problem and 5 equals no problem. The SWAL-QOL provides an overall score as well as subscale scores. Subjects rate quality of life as follows (expressed as percentage of the possible perfect score): little to no impact (81% - 100%), mild impact (61% - 80%), moderate impact (41% - 60%), severe impact (21% - 40%), and profound impact (0% - 20%).</description>
          <population>Out of the total 42 recruited study participants, ten either did not show up for the SWAL-QOL test or only partially answered the questionnaire. Thus, 32 remaining participants (n = 19 for EMST, and n = 13 for Sham) were reported.</population>
          <units>percentage of possible perfect score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-training total SWAL-QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="11.5"/>
                    <measurement group_id="O2" value="81.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-traing total SWAL-QOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="10.8"/>
                    <measurement group_id="O2" value="84.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Burden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" spread="20.0"/>
                    <measurement group_id="O2" value="80.8" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Burden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="7.3"/>
                    <measurement group_id="O2" value="86.2" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Pharyngeal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="16.9"/>
                    <measurement group_id="O2" value="75.4" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Pharyngeal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" spread="16.6"/>
                    <measurement group_id="O2" value="77.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Saliva</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="16.2"/>
                    <measurement group_id="O2" value="83.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Saliva</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="9.5"/>
                    <measurement group_id="O2" value="83.6" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" spread="7.0"/>
                    <measurement group_id="O2" value="91.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" spread="4.5"/>
                    <measurement group_id="O2" value="91.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Fear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="22.2"/>
                    <measurement group_id="O2" value="79.2" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Fear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" spread="20.4"/>
                    <measurement group_id="O2" value="84.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-training Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread="21.5"/>
                    <measurement group_id="O2" value="83.4" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-training Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="18.2"/>
                    <measurement group_id="O2" value="90.2" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <p_value_desc>EMST arm vs. Sham arm baseline total score and subscale score comparison</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <method>Plum Ordinal Regression Test</method>
            <method_desc>EMST arm vs. Sham arm group comparison of treatment response for total score and all subscale scores except for Burden and Pharyngeal domains</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Plum Ordinal Regression Test</method>
            <method_desc>EMST arm vs. Sham arm group comparison of treatment response in Burden domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Plum Ordinal Regression test</method>
            <method_desc>EMST arm vs. Sham arm group comparison of treatment response in Pharyngeal domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Sham arm post vs. pre-treatment comparison for the total SWAL-QOL score and subscale scores except for the Burden and Mental Health domains.</p_value_desc>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>Sham arm post vs. pre-treatment comparison in Burden domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>Sham arm post vs. pre-treatment comparison in Mental Health domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Burden domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Mental Health domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Pharyngeal domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Saliva domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Fear domain</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
            <method_desc>EMST arm post vs. pre-treatment comparison in Total SWAL-QOL score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Seven-week period (baseline testing at week 1, then 5 weeks of the experimental training, and post-training testing at week 7)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: EMST</title>
          <description>Expiratory Muscle Strength Trainer: Pressure threshold device targeted at increase muscle force generation of expiratory and submental muscles.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Sham Group</title>
          <description>Sham Device: Looks just like the EMST device but does not provide a load on the target muscle group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Janis Daly</name_or_title>
      <organization>North Florida/South Georgia Veterans Health System</organization>
      <phone>352-376-1611 ext 5223</phone>
      <email>janis.daly@neurology.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

